News

December 25, 2018

APRINOIA Therapeutics, a clinical-stage biotechnology company developing therapeutics and diagnostic imaging tools for neurodegenerative diseases, announced today that it has entered into a non-exclusive licensing agreement with Celgene Corporation. The agreement authorizes Celgene to use APN-1607, a novel investigational [  F]-labeled positron emission tomography (PET) imaging tracer, to suppo...

September 1, 2018
APRINOIA Will Participate Asia-China: 2018 Clinical Trials on Alzheimer’s Disease Conference
APRINOIA will sponsor the first Clinical Trials on Alzheimer's Disease Conference (CTAD) in Asia. The conference will take place in Shanghai on September 1st and 2nd. APRINOIA will be presenting the latest clinical data of our lead tau PET Imaging tracer, APN-1607 (PM-PBB3), and the current progress of our therapeutics programs at the conference.
January 16, 2018

APRINOIA Therapeutics Inc., a clinical-stage neuroscience biotech company, focuses on tau, alpha-synuclein, and novel targets for neurodegenerative diseases, announces today the completion of its US$11.1 million Series B round. The Series B round was led by KTB Network (Korea) and DCI Partners (Japan), along with participations from ShangPharma Investment Group (China) and TaiAn Technologies (T...

December 15, 2017
APRNIOIA Will participate 2018 Human Amyloid Imaging Conference
APRINOIA will present the latest result for its lead Tau PET Imaging Tracer APN-1607 (PM-PBB3) at the Human Amyloid Imaging (HAI) Conference in Miami in January 2018.
December 15, 2017
APRNIOIA Will Participate 2018 AAT-AD/PD Focus Meeting
APRINOIA will present the latest result for its lead Tau PET Imaging Tracer APN-1607 (PM-PBB3) and its tau therapeutic program at the 2018 AAT-AD/PD Focus Meeting in Torino in March 2018.
December 15, 2017
​APN-1607 (PM-PBB3) Receives US FDA Orphan Drug Designation
APRINOIA's lead tau PET imaging tracer, APN-1607 (PM-PBB3), has received US FDA Orphan Drug Designation.
December 12, 2016
APRINOIA Will Present its 1st Clinical Trial Results at 2017 Human Amyloid Imaging Conference
APRINOIA will present the first-in-the-human clinical trial results for its Tau PET Imaging Tracer APN-1607 (PM-PBB3) at the Human Amyloid Imaging (HAI) Conference in Miami in January 2017.
December 12, 2016
2017 International Conference on Alzheimer’s Disease and Parkinson’s Disease
APRINOIA will be presenting the first-in-the-human clinical trial result for its lead Tau PET Imaging Tracer APN-1607 (PM-PBB3) at the 13th International Conference on Alzheimer's Disease and Parkinson's Disease (AD&PD) in Vienna in March 2017.